Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coronado Biosciences has reported that the Bcl-2 inhibitor, apogossypol, effectively killed a variety of cancer cells in vitro while demonstrating less toxicity than its parent compound gossypol in vivo in mice.
Subscribe to our email newsletter
Published online in Blood by the Burnham Institute’s president and CEO, John Reed and collaborators, the paper summarized study findings demonstrating that mice treated with apogossypol experienced less hepatotoxicity and gastrointestinal toxicity than those treated with gossypol. The results support Coronado Biosciences’ continued development of its lead candidate, CNDO103, as a cancer treatment.
Dr Reed said: “This study provides strong evidence that apogossypol is better tolerated by the animals without a compromise in potency in vitro. We hope these preclinical results translate to humans. If they do, apogossypol can play a role in the treatment of many types of cancers.”
Coronado Biosciences plans to perform IND-enabling preclinical studies for CNDO103 in the first half of the year and if the toxicity profile in animals is favorable, the company plans to file an IND in late 2008.